New drug INI-4001 takes on advanced cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called INI-4001, alone or with standard immunotherapy, in people with advanced solid tumors that have spread. The main goal is to find a safe dose and check for side effects. About 50 adults with various cancers that cannot be cured with cu…
Phase: PHASE1 • Sponsor: Inimmune Corporation • Aim: Disease control
Last updated May 17, 2026 01:43 UTC